<DOC>
	<DOCNO>NCT02326103</DOCNO>
	<brief_summary>The study aim evaluate additional role ciprofloxacin therapy severe alcoholic hepatitis combine prednisolone therapy open-label placebo control manner .</brief_summary>
	<brief_title>Randomised Open-label Multicenter Study Evaluating Ciprofloxacin Severe Alcoholic Hepatitis</brief_title>
	<detailed_description>Introduction : Alcoholic hepatitis ( AH ) inflammatory liver injury associate longstanding excess alcohol consumption . Disease spectrum vary asymptomatic transaminase elevation fulminate liver failure . In hospital mortality patient severe alcoholic hepatitis respond corticosteroid 30 % . Alcohol increase gut permeability promote translocation lipopolysaccharide ( LPS ) gut lumen portal vein , Kupffer cell , LPS bind CD14 , ultimately activate multiple cytokine gene . Diagnosis AH base history heavy alcohol use , symptom like jaundice typical laboratory finding , uncertain case liver biopsy . Determination severity alcoholic hepatitis essential assessment disease prognosis selection therapy . Cessation alcohol consumption mandatory therapy . Several score system available assess severity prognosis alcohol hepatitis . Maddrey discrimination function ( DF ) widely use enables identify patient severe alcohol hepatitis respond corticosteroid therapy . The first line therapy severe alcoholic hepatitis ( DFâ‰¥32 ) prednisolone . However , respond steroid 77 % 6 month mortality . New treatment option severe AH desperately need . Although increased bacterial LPS translocation consider central role pathogenesis AH control study antibiotic alcoholic hepatitis publish . In Finland 600 AH require hospitalization diagnose annually . Study objective : To evaluate additional role ciprofloxacin therapy severe alcoholic hepatitis combine prednisolone therapy . Moreover , try find new good predictor liver injury treatment response . Patients : 150 AH patient , Maddrey DF &gt; 32 . Randomization : Patients severe AH randomize hospitalization 1:1 receive : 1 . Prednisolone 40 mg/day 1 month , decrease 5 mg/week + ciprofloxacin 1000 mg/ day 120 day 2 . Prednisolone 40 mg/day 1 month , decrease 5 mg/week + placebo/ day 120 day Measurement response Early change bilirubin level ( ECBL= S-Bil ( Day 0 ) -S-Bil ( Day7 ) &gt; 0 Lille Score &gt; 0.45 day 7 . Change serum sterol level surrogate marker cholesterol synthesis ( reflect liver function severity cholestasis ) Primary end point Mortality day 28 , 6 month 12 month Secondary end point : Proportion patient early change bilirubin level ( ECBL= S-Bil ( Day 0 ) -S-Bil ( Day7 ) &gt; 0 Proportion patient Lille Score &gt; 0.45 day 7 Recovery liver function parameter 1 3 month</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Liver Cirrhosis , Alcoholic</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Severe alcoholic hepatitis ; Maddrey 300 Viral hepatitis Remarkable bleed gastrointestinal tract Serious bacterial infection Hepatorenal syndrome Earlier participation study Malignant disease remission Other liver disease affect remarkably outcome alcoholic liver disease Mental retardation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>alcoholic</keyword>
	<keyword>hepatitis</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>cholesterol metabolite</keyword>
	<keyword>ciprofloxacin</keyword>
</DOC>